NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma

Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid

Download: PDF | Citation | XML
EzReprint New & improved!

Published in the February 2007 Issue of PLoS Medicine

Metrics info

Average Rating (0 User Ratings)

- Currently 0/5 Stars.
See all categories
1. Insight
  - Currently 0/5 Stars.
2. Reliability
  - Currently 0/5 Stars.
3. Style
  - Currently 0/5 Stars.
Rate This Article

Rate This Article

Please follow our guidelines for rating and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:

Remarks that could be interpreted as allegations of misconduct
Unsupported assertions or statements
Inflammatory or insulting language

Compose Your Annotation

Insight

Reliability

Style

Enter your comment title Enter your comment

Declare any competing interests.

No, I don't have any competing interests to declare.
Yes, I have competing interests to declare (enter below):

Ratings can include the following markup tags:

Emphasis: ''italic'' '''bold''' '''''bold italic'''''

Other: ^^^superscript^^ ~~_subscript~~

Metrics info

Average Rating (0 User Ratings)

Related Content

Share this Article info

NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma

Related Articles info

Related Articles on the Web

Bookmarked in

Related Blog Posts info

Trackbacks

Rate This Article